In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.
Tambone, S., Fargnoli, M., Capizzi, R., Peris, K., Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series, <<GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA>>, 2018; (june): N/A-N/A [http://hdl.handle.net/10807/70478]
Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series
Peris, Ketty
2015
Abstract
In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
